

<b>Name</b> Participants of WG3	<b>Bruno Ramos-Molina</b>
Affiliation	Obesity & Metabolism lab, Biomedical Research Institute of Murcia (IMIB)
Scientific expertise, up to 5 key words	Obesity, Metabolism, Nutrition, Diabetes, NAFLD
Motivation for participation in WG3	Among the projects related to NRF2, in our lab we are trying to study the NRF2/KEAP1 pathway in human livers from patients with NAFLD to really understand how alterations in this pathway could be involved in NASH physiopathology. We're also very interested in studying the possible role of NRF2 in liver cancer.
Short narrative biosketch, including scientific background/ education/major achievements etc.	<p>I currently head the Obesity &amp; Metabolism lab, a newly established research group (starting date: January 2020) of the Biomedical Research Institute of Murcia (IMIB). The establishment of this research group has been supported by funding of the Spanish Institute of Health Carlos III (ISCIII): Miguel Servet program (CP19/00098) and FIS grant (PI20/00505).</p> <p>Before the establishment of my own group, I performed two training postdoctoral research stays abroad from 01/2014 to 12/2016 (University of Maryland-Baltimore, USA; KU Leuven, Belgium). In addition, in 2017 I joined the Cellular and Molecular Endocrinology lab at the Biomedical Research Institute of Málaga (IBIMA) with the support of a Sara Borrell postdoctoral fellowship. During this reintegration period (3 years; from 01/2017 to 12/2019), I actively participated in previously established research lines related to the proposed research, including projects involving the analysis of gut microbiota and metabolic diseases (PI15/01114, PI18-00453), and I was able to develop new research lines as independent researcher focused on the study of the changes in the serum metabolome associated to obesity, type 2 diabetes and NAFLD with funding support from the Andalusian Health System (2017 call; grant number PI-00962017). In the last 5 years I have published more than 30 international publications (most of them as first, correspondence or senior author) indexed in PubMed (most of them in the first quartile/decile of their category) and closely related to the subject of the proposal, and I have participated as invited speaker in a number of national and international conferences and seminars.</p>
Current research topics/ongoing projects	<ol style="list-style-type: none"> <li>1) Unveiling the Role of Gut Microbiota and Epigenetics in NAFLD Pathogenesis</li> <li>2) Dietary Modulation of the Gut Microbiome in Patients with Colorectal Cancer</li> <li>3) Potential Health Benefits of Plant Food-Derived Bioactive Compounds in Obesity-Related Metabolic Disorders and Cancer</li> </ol>
Nfr2-related methodologies/ infrastructure/ equipment	We are currently studying the potential implication of the NRF2/KEAP1 pathway in the physiopathology of NAFLD by analyzing human samples from obese patients with different grades of NAFLD. So far, we have performed several IHC, qPCR and WB analysis in liver biopsies of NAFLD patients.
Available sample collections/datasets;	We have a collection of 100 patients with obesity recruited for bariatric surgery with a fully characterization of liver function, including histological analysis of liver biopsies. We have available liver tissue, adipose tissue,

interested in sharing; yes/no	intestinal tissue, blood (serum/plasma/PBMCs) and stool from all these patients at baseline. We also have blood and stool at 6-month and 12-month follow up visits after surgery. All samples are available for sharing between WG2/WG3 members upon request.
Available cohorts/ ongoing/planned human studies/grant applications	<ul style="list-style-type: none"> <li>- Bariatric cohort (see above).</li> <li>- CRC cohort (<a href="https://clinicaltrials.gov/ct2/show/NCT04869956">https://clinicaltrials.gov/ct2/show/NCT04869956</a>); patient recruitment.</li> </ul>
Interested in STSM: outgoing/hosting (year 1/later); yes/no	Interested in STMS (outgoing and hosting) in year 2 or later